Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Decrease of renal endothelin 1 content and gene expression in diabetic rats with moderate hyperglycemia

S J Shin1, Y J Lee, S R Lin

  • 1Department of Internal Medicine, Kaohsiung Medical College, Taiwan, ROC.

Nephron
|January 1, 1995
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A phase Ib/II, open-label, multicenter, randomized umbrella study evaluating the combination of atezolizumab with sacituzumab govitecan in patients with locally advanced or metastatic urothelial carcinoma and previously treated with a platinum-based treatment regimen (MORPHEUS-Urothelial Carcinoma).

ESMO open·2026
Same author

Novel pembrolizumab-based treatments as first-line therapy in advanced clear-cell renal cell carcinoma: substudy 03A of the open-label, umbrella platform, phase I/II KEYMAKER-U03 trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2025
Same author

Avelumab plus sacituzumab govitecan versus avelumab monotherapy as first-line maintenance treatment in patients with advanced urothelial carcinoma: JAVELIN Bladder Medley interim analysis.

Annals of oncology : official journal of the European Society for Medical Oncology·2025
Same author

Corrigendum to "An open-label, phase IB/II study of abemaciclib with paclitaxel for tumors with CDK4/6 pathway genomic alterations": [ESMO Open 10 (2025) 104106].

ESMO open·2025
Same author

An open-label, phase IB/II study of abemaciclib with paclitaxel for tumors with CDK4/6 pathway genomic alterations.

ESMO open·2025
Same author

Corrigendum to "Phase II study of a trastuzumab biosimilar in combination with paclitaxel for HER2-positive recurrent or metastatic urothelial carcinoma: KCSG GU18-18": [ESMO Open 8 (2023) 101588].

ESMO open·2024

Diabetic rats with hyperglycemia showed reduced intrarenal endothelin 1 (ET-1) synthesis. Insulin treatment improved ET-1 levels, suggesting a link between blood glucose control and kidney function in diabetes.

Area of Science:

  • Nephrology
  • Endocrinology
  • Molecular Biology

Background:

  • Diabetes mellitus is a complex metabolic disorder associated with significant renal complications.
  • Endothelin 1 (ET-1) plays a crucial role in regulating renal hemodynamics and function.
  • Altered ET-1 synthesis may contribute to diabetic nephropathy.

Purpose of the Study:

  • To investigate intrarenal endothelin 1 (ET-1) synthesis in streptozocin (STZ)-induced diabetic rats with moderate hyperglycemia.
  • To determine the impact of glycemic control on renal ET-1 levels in diabetic rats.

Main Methods:

  • Measurement of plasma ET-1, renal ET-1 mRNA, and renal tissue ET-1 levels in STZ-induced diabetic rats and control rats.
  • Assessment of kidney weight and glomerular filtration rate (GFR).

Related Experiment Videos

  • Evaluation of the effects of insulin treatment on renal ET-1 synthesis.

    • Main Results:

    • Renal ET-1 mRNA expression progressively decreased from week 2 to week 6 post-STZ injection.
    • Significantly reduced renal ET-1 mRNA and tissue levels were observed in hyperglycemic diabetic rats compared to normal rats.
    • Strict glycemic control with insulin ameliorated the reduction in renal ET-1 and mRNA levels.
    • Kidney weight and GFR were significantly increased in moderately hyperglycemic rats.

    Conclusions:

    • Moderate hyperglycemia in diabetic rats is associated with reduced intrarenal ET-1 synthesis.
    • Decreased renal ET-1 synthesis may be an adaptive response to early-stage diabetic renal hemodynamic changes.
    • Further investigation is warranted to elucidate the adaptive role of reduced renal ET-1 synthesis in diabetic kidney disease.